                               NIH Public Access
                               Author Manuscript
                               Cell Metab. Author manuscript; available PMC 2013 November 07.
                           Published final edited form 
NIH-PA Author Manuscript




                            Cell Metab. 2012 November 7; 16(5): 645â€“657. doi:10.1016/j.cmet.2012.10.001.



                           mTOR Regulates Cellular Iron Homeostasis                            Tristetraprolin
                           Marina Bayeva1, Arineh Khechaduri1, Sergi Puig2, Hsiang-Chun Chang1, Sonika Patial3,
                           Perry J. Blackshear3, Hossein Ardehali1,*
                           1Feinberg Cardiovascular Research Institute, Northwestern University School Medicine,

                           Chicago, 60611, USA
                           2Departamento BiotecnologÃ­a, Instituto AgroquÃ­mica y TecnologÃ­a Alimentos (IATA-
                           CSIC), P.O. Box 73, E-46100 Burjassot, Valencia, Spain
                           3Laboratory Signal Transduction; National Institute Environmental Health Science; Research
                           Triangle Park, NC 27709, USA
NIH-PA Author Manuscript




                           SUMMARY
                                 Iron essential cofactor unique redox properties. Iron regulatory proteins 1 2
                                 (IRP1/2) established important regulators cellular iron homeostasis, little                                  known role pathways process. report mammalian target
                                 rapamycin (mTOR) regulates iron homeostasis modulating transferrin receptor 1 (TfR1)
                                 stability altering cellular iron flux. Mechanistic studies identify tristetraprolin (TTP), protein
                                 involved anti-inflammatory response, downstream target mTOR binds                                  enhances degradation TfR1 mRNA. TTP strongly induced iron
                                 chelation, promotes downregulation iron-requiring genes mammalian yeast cells,
                                 modulates survival low-iron states. Taken  data uncover link                                  metabolic, inflammatory, iron regulatory pathways, point existence                                  yeast-like TTP-mediated iron conservation program mammals.


                           INTRODUCTION
                                              Iron deficiency anemia affects quarter worldâ€™s population   2008),                                               mechanisms iron regulation remain largely unexplored. Iron essential micronutrient
NIH-PA Author Manuscript




                                              required fundamental biological processes including oxygen delivery, protein synthesis,
                                              DNA replication oxidative phosphorylation (Arredondo Nunez, 2005). 
                                              ability iron easily gain lose electrons facilitates production reactive
                                              oxygen species (ROS) Fenton reaction (Aisen et al., 2001).  iron levels                                               tightly controlled cellular systemic levels deregulation iron homeostasis                                               associated aging, metabolic disorders cancer (Aisen et al., 2001; Altamura                                               Muckenthaler, 2009; Torti Torti, 2011; Weinberg, 2010).




                           Â© 2012 Elsevier  rights reserved.
                           *
                            Correspondence: h-ardehali@northwestern.edu.
                           Publisher's Disclaimer: PDF file unedited manuscript accepted publication. service                            customers providing early version manuscript. manuscript undergo copyediting, typesetting, review                            resulting proof published final citable form. note production process errors                            discovered affect content, legal disclaimers apply journal pertain.
                           authors declare conflicts                             Bayeva et al.                                                                                             Page 2


                                           Maintenance cellular iron homeostasis dependent RNA-binding iron regulatory
                                           proteins 1 2 (IRP1/2) activated iron-deficient conditions. IRP1/2
                                           function restore iron levels  1) stabilization transferrin receptor 1 (TfR1)
NIH-PA Author Manuscript




                                           mRNA increased iron uptake, 2) mobilization cellular iron stores, 3) reduction                                            cellular iron export suppression ferroportin 1 (Fpn1), cellular iron
                                           exporter identified date (Hentze et al., 2010; Rouault, 2006; Wang Pantopoulos,
                                           2011). Additionally, iron conservation response recently described S.
                                           cerevisiae coordinated expression tandem zinc finger (TZF) proteins Cth1p                                            Cth2p causes destabilization mRNAs nonessential iron-containing proteins                                            libration iron use vital processes (Pedro-Segura et al., 2008; Puig et al., 2005; Puig
                                           et al., 2008). mammalian homolog Cth1p/Cth2p, tristetraprolin (TTP),                                            extensively studied context immunosuppression (Baou et al., 2009), role                                            iron regulation known.

                                           Mammalian target rapamycin (mTOR) important sensor cellular energy state                                            major hub integration environmental cues (Howell Manning, 2011; Sengupta et
                                           al., 2010). complex activated energetically favorable, low-stress states                                            adverse conditions, starvation, cytotoxic insults DNA damage, act inhibit
                                           mTOR signaling promote survival conservation cellular resources (Dunlop
                                           Tee, 2009; Soliman, 2005). processes governed mTOR dependent                                            iron factor require steady supply metal. appears NIH-PA Author Manuscript




                                           link iron homeostasis mTOR, clinical use rapamycin associated                                            development microcytic anemia mechanistically distinct anemia                                            chronic disease (Kim et al., 2006; Maiorano et al., 2006; Sofroniadou et al., 2010).                                             establish mTOR pathway regulator iron homeostasis acts modulation
                                           iron transporters alteration cellular iron flux.  identify TTP                                            target mTOR   modulates iron-regulatory effects                                            destabilization TfR1 mRNA.

                              RESULTS
                              mTOR regulates cellular iron homeostasis
                                           mTOR activation stimulates important anabolic processes depend                                            presence iron cofactor;  hypothesized mTOR play role                                            regulation cellular iron availability utilization. test  modulated mTOR
                                           signaling wild type (WT) mouse embryonic fibroblasts (MEFs) H9c2 cardiac
                                           myoblasts followed quantification heme non-heme iron content. Rapamycin
                                           effectively inhibited mTOR signaling cell lines (Figure 1A), assessed                                            ablation pS6 expression. Treatment rapamycin led significant increase NIH-PA Author Manuscript




                                           non-heme heme iron content MEFs (Figure 1B S1A) H9c2 cells (Figure
                                           S1B,C). Consistent elevation iron levels, protein content ferritin light chain,                                            iron storage molecule, significantly increased rapamycin treatment WT MEFs
                                           (Figure S1D). Increased heme levels likely inhibition heme degradation,                                            mRNA levels heme oxygenase 1 (HMOX1) significantly decreased,                                            expression key heme synthetic enzymes, Î´-aminolevulinic acid synthase 1 (ALAS1)                                            ferrochelatase, remained unchanged (Figure S1E). activate mTOR, used TSC2
                                           knockout MEFs upstream inhibitor pathway genetically deleted                                            pS6 levels increased (Figure 1A). knockout MEFs transfected                                            pEF6 vector (referred TSC2 KO-V MEFs) pEF6/TSC2 vector                                            reconstitute TSC2 expression knockout MEFs (TSC2 KO-TSC2 MEFs), followed                                            selection blasticidin generate stable transgenic cell lines described (Zhang et al.,
                                           2003). Constitutive activation mTOR TSC2 KO-V MEFs decreased heme non-


                                               Cell Metab. Author manuscript; available PMC 2013 November 07.
                            Bayeva et al.                                                                                            Page 3


                                           heme iron, rapamycin restored levels control (Figure 1C S1F),
                                           indicating observed changes mTOR modulation.
NIH-PA Author Manuscript




                                           determine changes cellular iron resulted alterations iron import,                                            measured uptake radioactive iron (55Fe) mTOR modulation. Unexpectedly,
                                           rapamycin treatment significantly reduced iron uptake, TSC2 KO-V MEFs TSC2
                                           siRNA-treated H9c2 myoblasts displayed enhancement iron uptake 60 minutes                                            incubation (Figure 1D,E S1G,H). differences persisted 24 hours                                            growth 55Fe cell lines (Figure 1F,G S1I,J). results suggest                                            inhibition mTOR results cellular iron accumulation despite reduction iron uptake,
                                           mTOR activation opposite effect.

                                           studied mechanism observations measuring expression genes
                                           involved iron regulation MEFs H9c2 (Anderson Vulpe, 2009; Hentze et al.,
                                           2010). Consistent decreased iron uptake, rapamycin significantly reduced                                            mRNA protein levels transferrin receptor 1 (TfR1) required uptake                                            transferrin-bound iron (Figure 2A,C). Additionally, TfR1 levels reduced MEFs                                            H9c2 treated Torin-1, specific inhibitor mTOR pathway (Figure S2A).
                                            mRNA protein levels iron exporter, Fpn1, reduced                                            rapamycin Torin-1 (Figure 2B,C, Figure S2A). Consistently, mTOR activation
                                           increased expression TfR1 Fpn1, rapamycin suppressed effect (Figure
NIH-PA Author Manuscript




                                           2D). results suggest mTOR inhibition leads coordinated reduction                                            expression TfR1 Fpn1, resulting net accumulation cellular iron, mTOR
                                           activation opposite effect.

                                           addition effects TfR1 Fpn1, rapamycin led global suppression                                            iron-regulatory genes MEFs H9c2, consistent reduction cellular iron flux,
                                           opposite observed activation mTOR (Figure S2Bâ€“E). contrary,                                            downregulation genes involved regulation cellular iron                                            rapamycin treatment WT MEFs (Figure 2E), suggesting effects iron regulatory
                                           network specific, represent artifact generalized transcriptional
                                           repression.

                              TfR1 target mTOR
                                           Concurrent decrease expression protein mediating iron import (TfR1) iron
                                           exporter (Fpn1) rapamycin raises possibilities.  mTOR inhibition                                            negatively regulate expression TfR1, leading reduced iron import net iron loss
                                           cell. resulting deficiency activate IRP1/2 subsequent inhibition                                            Fpn1 prevent iron loss (Figure S3A). Alternatively, rapamycin primarily
NIH-PA Author Manuscript




                                           target Fpn1 leading cellular iron accumulation decreased export.                                            suppress IRP1/2 activity secondarily reduce TfR1 levels stop iron gain                                            import (Figure S3B). distinguish possibilities, assessed time-
                                           course TfR1 Fpn1 expression 24 hours rapamycin treatment.                                            observed steady decrease TfR1 mRNA levels rapamycin, Fpn1 expression
                                           initially upregulated 2 4 hours, followed decline (Figure 3A). findings
                                           point possibility mTOR primarily regulating TfR1 expression,                                            changes Fpn1 secondary effect (Figure S3A). Consequently, focused                                            efforts studying regulation TfR1 mTOR.

                                           uncover mechanism mTOR regulates TfR1, assessed stability
                                           TfR1 mRNA rapamycin treatment. Incubation rapamycin-treated MEFs                                            transcriptional inhibitor actinomycin D led significant reduction TfR1 mRNA
                                           stability relative control group (Figure 3B), suggestive post-transcriptional


                                               Cell Metab. Author manuscript; available PMC 2013 November 07.
                            Bayeva et al.                                                                                            Page 4


                                           regulation. key known post-transcriptional regulators TfR1 IRP1/2 proteins,
                                            hypothesized, mediate mTOR-dependent changes TfR1. determine
                                           IRP1/2 pathway mediates suppression TfR1 rapamycin, downregulated IRP1
NIH-PA Author Manuscript




                                           expression IRP2 KO MEFs using siRNA approach (IRP1/2 KD/KO MEFs),                                            resulted significant knockdown IRP1 expression (Figure 3C) reduction TfR1
                                           mRNA, consistent functional inhibition IRP1/2 pathway (Figure S3C).
                                            repression TfR1 rapamycin intact IRP1/2 KD/KO MEFs
                                           (Figure 3D), indicating regulation TfR1 mTOR independent IRP1/2
                                           pathway.

                              TTP functionally similar iron-regulating yeast Cth1p/Cth2p proteins
                                           Recent studies S. cerevisiae TZF proteins, Cth1p Cth2p, regulate cellular
                                           iron homeostasis binding AU-rich elements (AREs) destabilizing mRNAs                                            iron-requiring proteins salvaging iron use essential functions (Puig et al., 2005).
                                           showed IRP1/2 proteins mediate effects mTOR TfR1,                                            hypothesized TZF proteins regulate TfR1 cellular iron homeostasis                                            mammals. TZF proteins homology Cth1p Cth2p, TTP (ZFP36), CMG1
                                           (Zfp36l1) TIS11D (Zfp36l2), identified mammals (Baou et al., 2009)                                            studied context cytokine signaling (Carrick et al., 2004). determine                                            proteins modulate iron homeostasis similar Cth1p/Cth2p yeast, assessed
                                           regulation cellular iron levels. Iron chelation DFO resulted significant NIH-PA Author Manuscript




                                           dose-dependent upregulation TTP mRNA (Figure 3E) protein expression (Figure 3F).
                                           Treatment 2,2â€“bipyridyl (2,2-BPD), lipophilic iron chelator mechanistically
                                           distinct DFO, induced TTP expression (Figure 3G), suggesting observed
                                           effect reduction cellular iron restricted DFO. 
                                           iron overload ferric ammonium citrate (FAC) suppressed TTP expression (Figure 3G).
                                           mRNA levels TZF proteins increased DFO MEFs                                            H9c2 cells (Figure S3D,E),  excluded subsequent studies                                            lack regulation mTOR (Figure S3F,G). Taken  results  similar
                                           Cth1p/Cth2p yeast, TTP regulated cellular iron status mammals.

                                           confirm functional similarity Cth1p/Cth2p TTP, studied                                            ability TTP reduce expression containing iron-requiring proteins (ABCE1,
                                           Fe/S cluster protein involved ribosome biogenesis Lias, lipoic acid synthase)
                                           (Figure S3H). Similar yeast, iron chelation reduced expression ABCE1 Lias                                            WT MEFs (Figure 3H), did suppress mRNA levels proteins                                            require iron function (Figure S3I).  mRNA levels ABCE1 Lias
                                           increased TTP KO MEFs (Figure 3I S3J), ABCE1 levels reduced                                            TTP overexpression WT MEFs (Figure S3J,K), confirming inhibitory function NIH-PA Author Manuscript




                                           TTP. DFO treatment TTP KO MEFs failed decrease, instead led                                            exaggerated increase expression ABCE1 Lias (Figure 3J), suggesting TTP
                                           critical repression iron-containing proteins iron chelation. Finally,                                            determine mammalian TTP complement Cth1p/Cth2p deletion yeast,                                            expressed WT TZF-mutant allele human TTP (C124R) (Lai et al., 1999)                                            control iron-regulated CTH2 promoter yeast cells. Similar MEFs, treatment
                                           Cth1Î”Cth2Î” yeast iron chelator bathophenanthroline (BPS) led increase                                            mRNA levels known Cth1p/Cth2p targets, succinate dehydrogenase subunit 4
                                           (SDH4) aconitase (ACO1), transfection cells Cth2 plasmid restored
                                           suppression iron-containing genes iron deficiency (Figure 3K). 
                                           overexpression WT human TTP, C124R construct, reduced mRNA levels
                                           SDH4 ACO1 iron-limiting conditions, suggestive functional conservation
                                           yeast Cth1p/Cth2p mammalian TTP (Figure 3K). Taken  findings


                                               Cell Metab. Author manuscript; available PMC 2013 November 07.
                            Bayeva et al.                                                                                            Page 5


                                           suggest role TTP regulation cellular iron homeostasis similar                                            performed yeast Cth1p/Cth2p, suppressing expression iron-containing
                                           proteins potentially optimizing iron utilization low-iron states.
NIH-PA Author Manuscript




                              mTOR regulates TTP expression
                                            assessed mTOR regulates expression TTP. Rapamycin treatment                                            MEFs H9c2 cells induced expression TTP mRNA protein (Figure 4A,B                                            S4A). Significant upregulation TTP mRNA observed Torin-1 treated MEFs
                                           H9c2 cells (Figure S4B,C). TTP levels suppressed mTOR activation TSC2
                                           KO-V MEFs, rapamycin reversed effects (Figure 4C).  rapamycin
                                           treatment WT MEFs resulted significant decrease levels stability TTP
                                           targets ABCE1 Lias, consistent TTP induction (Figure S4D,E). Treatment cells
                                           rapamycin DFO led greater induction TTP expression agent
                                           (Figure S4F), suggesting additive effect. Importantly, downstream effects                                            TTP rapamycin iron regulation independent inflammatory response,                                            did detect TNFÎ± mRNA expression MEFs H9c2 cells (Figure S4G,H). Finally,
                                           determine regulation TZF proteins mTOR conserved                                            eukaryotic organisms, treated WT yeast strain rapamycin observed significant
                                           induction Cth1 Cth2 mRNA (Figure 4D), consistent observations                                            mammalian cells.
NIH-PA Author Manuscript




                                           mTOR cellular iron status known regulate hypoxia-inducible factor
                                           (HIF) signaling, assessed TTP regulation aryl hydrocarbon receptor nuclear
                                           translocator (ARNT) KO MEFs lack obligate binding partner HIF1Î± HIF2Î±,
                                           disrupting HIF pathway (Patel Simon, 2008). TTP levels increased
                                           DFO rapamycin treatment ARNT KO MEFs (Figure 4E,F), indicating                                            observed regulation HIF-independent.  observed significant induction                                            TTP expression IRP1/2 KD/KO MEFs (Figure 4G,H), suggesting activity                                            IRP1/2 does mediate upregulation TTP expression rapamycin                                            DFO. summary, TTP negatively regulated mTOR pathway HIF-
                                           IRP1/2-independent manner.

                              TTP associates regulates TfR1 mRNA
                                           TTP modulates cellular iron homeostasis downstream target mTOR,                                            hypothesized TTP regulate TfR1. Computational analysis 3â€™UTR TfR1
                                           revealed multiple putative AREs, close proximity                                            overlapped IREs (Figure S5A). Consistently, TfR1 mRNA levels                                            increased TTP KO MEFs (Figure 4I) TTP siRNA H9c2 cells (Figure S5B),
NIH-PA Author Manuscript




                                           TTP overexpression reduced TfR1 levels MEFs (Figure 4J).  TfR1
                                           mRNA significantly stabilized TTP KO MEFs presence actinomycin D
                                           (Figure 4K), confirming TTP regulates TfR1 expression level mRNA stability.

                                           determine TTP regulates TfR1 mRNA 3â€™UTR, cloned length
                                           3â€™UTR mouse TfR1 downstream firefly luciferase gene (TfR1-3â€™UTR-Luc, Figure
                                           5A), used renilla luciferase construct normalize transfection efficiency. Consistent
                                           TTP suppression TfR1 3â€™UTR, transfection TfR1-3â€™UTR-Luc construct
                                           WT MEFs overexpressing TTP led significant reduction luminescence signal
                                           (Figure 5B), luminescence increased TTP KO MEFs (Fig 5C).

                                           Finally, assess interaction TTP TfR1 mRNA, performed RNA 
                                           immunoprecipitation (RNA IP) experiment using anti-TTP control IgG antibody
                                           bait analyzing mRNA targets TTP qRT-PCR (Table 1), described previously


                                               Cell Metab. Author manuscript; available PMC 2013 November 07.
                            Bayeva et al.                                                                                           Page 6


                                           (Emmons et al., 2008). monoclonal antibody used studies raised                                            human TTP, pull experiments performed human HEK293 cells.                                            designed distinct primer sets TfR1 target regions near 3â€™UTR, primer
NIH-PA Author Manuscript




                                           sets positive controls. observed enrichment known targets TTP
                                           (VEGF (Essafi-Benkhadir et al., 2007) Pitx-2 (Briata et al., 2003)) TTP antibody
                                           group compared IgG, enrichment observed negative
                                           controls tested (Table 1). TfR1 mRNA levels significantly enriched TTP group
                                           compared IgG control (Table 1, Figure 5D), indicative interaction TTP
                                           TfR1 mRNA. Taken  results TTP induced rapamycin                                            regulates TfR1 expression posttranscriptional level.

                              mTOR regulates iron homeostasis TTP
                                           Finally, asked TTP mediates changes TfR1 expression observed                                            mTOR modulation. TTP KO MEFs incubated rapamycin, expression                                            TfR1 assessed. TTP WT MEFs, rapamycin led expected ~50  decrease                                            TfR1 levels;  TTP KO MEFs reduction TfR1 expression significantly
                                           blunted (Figure 5E). Furthermore, expression containing iron-requiring
                                           proteins reduced rapamycin WT MEFs, response greatly attenuated                                            TTP KO MEFs (Figure 5F). Finally, TfR1 mRNA stability reduced WT MEFs
                                           incubated rapamycin, TTP KO MEFs (Figure 5G). results establish
                                           TTP downstream target mTOR, activity partially responsible NIH-PA Author Manuscript




                                           mTOR-dependent regulation TfR1.

                                           shown TTP regulates TfR1 mRNA stability, significance TfR1
                                           downregulation setting iron deficiency respect IRP1/2 pathway                                            unclear. hypothesized TTP acts â€œbrakeâ€? IRP1/2 prevent                                            unnecessary activation iron uptake cell reducing iron use TTP-
                                           dependent downregulation iron-containing proteins. correct, hypothesis predicts
                                           exaggerated induction TfR1 iron deficiency absence TTP, higher levels
                                           TTP blunt TfR1 upregulation iron chelation. Consistently,                                            degree TfR1 upregulation significantly greater DFO-treated TTP KO MEFs
                                           compared chelated TTP WT MEFs (Figure 5H), combination DFO                                            rapamycin, additive effect TTP upregulation (Figure S4F), led                                            attenuation TfR1 induction compared DFO (Figure S5C).

                                           assess functional importance TTP regulation cellular iron, measured                                            survival TTP KO MEFs iron-deficient conditions. hypothesized TTP                                            protective low iron states, deletion result increased cell death iron
                                           chelation. Consistently, observed significant drop cell viability TTP KO MEFs
NIH-PA Author Manuscript




                                           treated 250ÂµM DFO 250ÂµM 2,2-BPD 40 hrs (Figure 5I). addition, TTP KO
                                           MEFs exquisitely sensitive serum deprivation (Figure S5D), main
                                           source iron growth medium (Kakuta et al., 1997), glutamine deprivation
                                           (Figure S5D), indicative tolerance TTP KO MEFs general cellar stressors.
                                           Supplementation TTP KO MEFs transferrin-bound iron significantly,                                            completely, reversed effects serum deprivation cell viability, effect
                                           viability TTP KO MEFs grown serum-replete medium (Figure S5E). findings
                                           suggest TTP KO MEFs reduced cell viability deprived iron compared                                            TTP WT MEFs.

                                           determine cell death iron-deficient TTP KO MEFs mediated mTOR
                                           pathway, pre-treated TTP KO MEFs rapamycin 6 hours, followed 
                                           incubation DFO 2,2-BPD. Surprisingly, rapamycin significantly attenuated cell
                                           death iron chelation (Figure 5J). Analysis cell cycle progression revealed

                                               Cell Metab. Author manuscript; available PMC 2013 November 07.
                            Bayeva et al.                                                                                          Page 7


                                           significantly higher baseline division rates TTP KO MEFs compared TTP WT MEFs
                                           (Figure S5F), defect cell cycle arrest response DFO (Figure S5G,H).                                            hand, pre-treatment TTP KO MEFs rapamycin prior chelation DFO NIH-PA Author Manuscript




                                           equally suppressed cell cycle progression TTP KO TTP WT MEFs (Figure S5G,H),
                                           suggesting rapamycin-dependent preservation viability TTP KO MEFs                                            suppression cell division TTP KO MEFs.

                                           summary, results suggest mTOR regulates cellular iron homeostasis TfR1
                                           expression TTP inhibition function negative feedback loop fine-
                                           tune iron deficiency response maintain cell viability low-iron states.

                              mTOR TTP regulate iron homeostasis vivo
                                           far data suggest mTOR TTP regulate expression TfR1 iron
                                           homeostasis MEFs H9c2 cells. determine pathways play role                                            regulation iron homeostasis vivo, treated c57 black WT mice 5 daily
                                           intraperitoneal (IP) injections rapamycin inhibit mTOR, studied iron
                                           regulation triple TTP- TNFÎ± receptors 1 2 knockout (TTP/TNFR1/2 KO) mice.
                                           mice deletion TTP display profound inflammation primarily                                            stabilization TNFÎ± (Taylor et al., 1996), TTP/TNFR1/2 triple-KO mice                                            inflammatory phenotype year age (Carballo Blackshear, 2001)                                            represent suitable model study iron regulation.
NIH-PA Author Manuscript




                                           Treatment WT mice IP rapamycin successfully inhibited mTOR signaling,                                            evidenced absence pS6 expression (Figure S6A). Similar vitro findings,
                                           nonheme heme iron levels increased (Figure 6A,B), expression TfR1
                                           Fpn1 reduced (Figure 6C,D), hearts rapamycin-treated mice. TTP
                                           expression induced rapamycin mouse hearts (Figure 6D), suggesting                                            protein potentially mediate TfR1 expression vivo. Surprisingly, assessment                                            rapamycin effects hepatic iron homeostasis revealed reduced non-heme iron levels
                                           (Figure S6B) decrease TfR1, preservation Fpn1 expression (Figure S6C,D).
                                           suggests rapamycin primarily reduces uptake iron liver, leading                                            export-dependent iron loss. Finally, rapamycin effect expression                                            systemic iron-regulatory hormone hepcidin upstream regulators, bone
                                           morphogenic protein 6 (BMP6) hemojuvelin (HJV) (Figure S6E).  rapamycin
                                           appears primarily affect iron regulation cellular level vitro vivo.

                                           assessed effects TTP deletion iron regulation TTP/TNFR1/2 KO                                            WT littermate control mice. Consistent vitro findings, TfR1 protein levels                                            significantly induced TTP-deficient mouse hearts (Figure 6E), corresponded NIH-PA Author Manuscript




                                           increase cardiac non-heme iron content (Figure 6F) elevated levels iron storage
                                           protein ferritin (light heavy chains) (Figure 6G).  reduction                                            levels Fpn1 protein TTP deletion (Figure 6G). Analysis iron homeostasis TTP-
                                           deficient livers revealed significant change non-heme iron content (Figure S6F),
                                           TfR1or ferritin light chain protein (Figure S6G),  similar heart, Fpn1 protein
                                           expression suppressed. determine suppression Fpn1 protein                                            increased expression subsequent degradation hepcidin, measured levels                                            peptide TTP-deficient mouse livers.  consistent unaltered hepatic iron
                                           levels, protein content hepcidin similar TTP/TNFR1/2 KO WT mice
                                           (Figure S6H), suggesting different mechanism Fpn1 downregulation heart                                            liver. Taken  data mTOR TTP regulate TfR1 iron
                                           homeostasis vitro vivo, providing iron-regulatory pathway likely
                                           complements cellular functions IRP1/2.



                                               Cell Metab. Author manuscript; available PMC 2013 November 07.
                            Bayeva et al.                                                                                            Page 8


                              DISCUSSION
                                           Iron essential catalysis reactions appears intimate link
NIH-PA Author Manuscript




                                           iron energy metabolism. Short-term iron deficiency known promote
                                           insulin sensitivity, iron overload lead glucose intolerance (Dongiovanni et al.,
                                           2008; Liu et al., 2009). Iron accumulation linked non-alcoholic fatty liver disease,
                                           cause alteration function adipocytes ability oxidize glucose
                                           (Dongiovanni et al., 2011). cellular level, circumstantial evidence points                                            cross-talk energy sensing iron regulatory pathways, exemplified study
                                           Galvez et. al. identifies mTOR positive regulator transferrin-bound iron
                                           uptake (Galvez et al., 2007), iron deficiency shown inhibit mTOR signaling
                                           (Ndong et al., 2009; Ohyashiki et al., 2009).  direct systematic studies                                            mTOR iron regulation lacking.  pathway links mTOR,                                            major metabolic hub cell, regulation cellular iron uptake flux                                            modulation TfR1 expression. mechanism observed changes partially
                                           mediated TZF protein TTP, induced rapamycin, interacts TfR1
                                           mRNA leads degradation (Figure 6H).  provide evidence
                                           TTP functions mammals similar yeast Cth1p/Cth2p regulating
                                           cellular iron reduction levels iron-containing proteins preservation                                            cell viability iron deficiency.
NIH-PA Author Manuscript




                                           possible vitro changes cellular iron content mTOR modulation                                            solely explained differential rates cellular division â€œiron-dilutionâ€? effect,                                            increased iron levels rapamycin-treated terminally-differentiated mouse hearts argue
                                           possibility.  repressive effects rapamycin genes involved                                            cellular iron regulation specific pathway global transcriptional
                                           inhibition, levels iron-independent genes unaltered                                            increased rapamycin treatment. magnitude change iron levels mTOR
                                           modulation modest, suggesting mTOR fine-tune cellular iron utilization match
                                           metabolic requirements cell. Alternatively, modest change iron mTOR
                                           inhibition agreement hypothesis TTP involved iron conservation
                                           response. IRP1/2 activation enhances cellular iron uptake reduces export leading
                                           iron accumulation, TTP primarily affects distribution iron molecules                                            present cell large induction iron import storage. exact role TTP
                                           regulation iron homeostasis various environmental conditions remains                                            determined;  data highlight importance pathway low-iron states,
                                           evidenced severe loss cell viability iron deficiency TTP knockout.

                                           fact TTP reduces TfR1 mRNA levels stability surprising. TTP
NIH-PA Author Manuscript




                                           strongly induced low iron levels different cell lines mouse hearts,                                            mechanistically distinct chelators.  appears counterintuitive TTP signals                                            degrade TfR1 message IRP1/2 concurrently stabilize mRNA. similar situation
                                           described yeast cells Aft1p  yeast homolog IRP1/2) activates                                            transcription FIT1 FIT2 genes involved iron uptake, Cth2p promotes                                            degradation response iron deficiency (Puig et al., 2005). hypothesize parallel
                                           activation pathways serves fine-tune TfR1 levels based severity iron
                                           deficiency degree reduction cellular iron utilization TTP. levels                                            iron-containing proteins decrease iron available, need additional
                                           import iron  corresponding reduction TfR1 levels. words,
                                           TTP act â€œbrakeâ€? IRP1/2 response better match rate iron import
                                           actual needs cell spare exogenous iron use tissues.                                            relative contribution TTP IRP1/2 pathways iron deficiency response remains                                            determined;  significant sequence overlap AREs IREs, binding


                                               Cell Metab. Author manuscript; available PMC 2013 November 07.
                            Bayeva et al.                                                                                          Page 9


                                           sites TTP IRP1/2, respectively, suggests possibility steric hindrance effects.
                                            rapid activation IRP1/2 slower transcriptional induction TTP                                            iron deficiency provide additional degree regulation, IRP1/2 serving
NIH-PA Author Manuscript




                                           rapid response aimed correcting iron deficiency enhancing iron uptake.                                            unsuccessful, TTP-mediated iron-conservation program subsequently induced,
                                           allowing cells survive chronic iron deficiency.

                                           addition TTP, data suggest existence  unidentified, pathway
                                           mediating mTOR-dependent changes iron homeostasis.  observed                                            significant attenuation, complete reversal rapamycin effects TTP KO MEFs.
                                           Second, rapamycin administration caused rapid progressive reduction TfR1
                                           mRNA levels, reaching significance hours treatment (n=18). induction
                                           TTP rapamycin represents later-stage response, acute mechanism,                                            phosphorylation event microRNA processing, explain findings.                                             presently unclear TTP expression regulated mTOR. induction                                            TTP rapamycin unaltered MEFs defective HIF IRP1/2 signaling, suggesting
                                           pathways involved mTOR-dependent regulation TTP.                                            unlikely rapamycin regulates TTP levels indirectly increase cellular iron
                                           levels, rapamycin iron chelation DFO additive,                                            opposing, effect TTP induction.  pathways downstream mTOR play                                            role regulation TTP cellular iron homeostasis.  data NIH-PA Author Manuscript




                                           exclude possibility independent roles mTOR TTP pathways regulation                                            TfR1 iron homeostasis. Extensive characterization molecular networks,
                                           environmental signals downstream effectors pathways shed light                                            biological role iron regulation.

                                           summary, identified mTOR TTP new players cellular iron homeostasis                                            regulate mRNA stability TfR1 iron-containing genes.  described                                            existence Cth1p/Cth2p-like pathway mammalian cells represent                                            important iron-deficiency response mechanism functions parallel 
                                           established IRP1/2 regulatory 

                              EXPREIMENTAL PROCEDURES
                              Cell culture reagents
                                           MEFs grown complete DMEM medium (Cellgro, VA) supplemented 10  FBS
                                           (Invitrogen, CA) 1  penicillin-streptomycin (P/S). glutamine-deprivation
                                           experiments Cellgro DMEM L-glutamine (Cat. # 15-013-CV) used.                                            genetically modified MEF lines compared matched WT MEFs obtained NIH-PA Author Manuscript




                                           littermate control mouse. TSC2 KO-V TSC2 KO-TSC2 MEFs described
                                           previously (Zhang et al., 2003). TTP KO (line 66) TTP WT (line 67) MEFs                                            derived littermate E14.5 embryos described (Taylor et al., 1996). ARNT KO MEFs
                                           generous gift Dr. Celeste Simon (Maltepe et al., 1997). IRP1 KO IRP2 KO
                                           MEFs kindly provided Dr. Tracey  Rouault. H9c2 cardiac myoblasts                                            purchased ATCC kept complete DMEM medium (ATCC, VA) 10  FBS
                                           1  P/S. H9c2 MEF cells treated 20nM rapamycin (LC Labs, MA) 24
                                           48 hours, 150ÂµM DFO 200ÂµM 2,2-BPD 16â€“24 hours unless specifically noted,                                            50Âµg/ml FAC 16 hrs (Sigma-Aldrich, USA).




                                              Cell Metab. Author manuscript; available PMC 2013 November 07.
                            Bayeva et al.                                                                                         Page 10


                              siRNA treatment
                                             H9c2 cells transfected siRNA using DharmaFect (Thermo Scientific,  reagent
                                             according manufacturerâ€™s protocol. Rat TSC2 siGENOME siRNA (Thermo Scientific,
NIH-PA Author Manuscript




                                              rat TTP FlexiTube siRNA (Quiagen, CA) used.

                              Quantitiative RT-PCR
                                             RNA isolated RNA STAT-60 (TEL-TEST,  TX), reverse-transcribed                                              Random Hexamer (Applied Biosystems, CA), amplified 7500 Fast Real-Time PCR
                                             SYBR Green PCR Master Mix (Applied Biosystems, CA). Primers                                              designed using Primer3 (v. 0.4.0) software target sequences spanning exon-intron-exon
                                             boundary. mRNA levels calculated comparative threshold cycle method                                              normalized Î²-actin HPRT gene.

                              Western blot
                                             30 Âµg protein resolved SDS-PAGE gels transferred nitrocellulose
                                             membranes (Invitrogen, CA) probed antibodies pS6 (Cell
                                             Signaling, MA), TfR1 (Invitrogen, CA), Slc40A1 (Fpn1, Novus Biologicals, , TTP (Cao
                                             et al., 2004) Tubulin (Abcam, MA). HRP-conjugated donkey anti-rabbit donkey
                                             anti-mouse used secondary antibodies (Santa Cruz, CA) visualized Pierce
                                             SuperSignal Chemiluminescent Substrates.
NIH-PA Author Manuscript




                              Plasmid transfections
                                             Plasmids transfected MEFs using Lipofectamine reagent (Invitrogen, CA)                                              OptiMEM (Cellgro, VA) hours, followed incubation complete, antibiotic-free
                                             medium 20 hours.

                              Non-heme heme iron assays
                                             Non-heme iron measured described (Rebouche et al., 2004). Briefly, equal amounts
                                             protein mixed protein precipitation solution (1:1 1N HCl 10 
                                             trichloroacetic acid) heated 95Â°C 1h release iron. Precipitated protein                                              removed centrifugation 4Â°C 16,000 Ã— g 10 minutes, supernatant                                              mixed equal volume chromogen solution (0.5mM ferrozine, 1.5M sodium
                                             acetate, 0.1  (v/v) thioglycolic acid) absorbance measured Spectra Max Plus
                                             microplate reader 562 nm. Heme quantified described (Ward et al., 1984). Briefly,
                                             equal amounts protein mixed 2M oxalic acid, heated 95Â°C 30 minutes                                              release iron heme generate protoporphyrin IX. Samples centrifuged                                              10 min 1,000 Ã— g 4Â°C remove debris, fluorescence supernatant NIH-PA Author Manuscript




                                             assessed 405nm / 600nm Spectra Max Gemini fluorescence microplate reader.

                              55Fe    uptake studies
                                             55Fe  (Perkin-Elmer, MA) conjugated nitriloacetic acid (NTA, Sigma-Aldrich, USA)
                                             dissolved final concentration 100â€“300nM complete, serum-containing
                                             medium 24 hours prior beginning experiments. MEFs H9c2 incubated
                                             1 hour 24 hours 55Fe-containing complete medium, washed 3 times ice-
                                             cold 500mM BPS PBS remove membrane-associated 55Fe lysed 1 
                                             Triton-X100 TBS. radioactivity sample determined Beckman
                                             scintillation counter normalized protein content sample.




                                                Cell Metab. Author manuscript; available PMC 2013 November 07.
                            Bayeva et al.                                                                                         Page 11


                              mRNA stability assay
                                           MEFs incubated complete medium supplemented 5ÂµM actinomycin D
                                           (Sigma-Aldrich, USA) 3â€“6 hours. drop cell viability observed end NIH-PA Author Manuscript




                                           treatment. RNA collected mRNA levels analyzed qRT-PCR                                            described 

                              RNA-CoIP
                                           protocol adapted Emmons et. al (Emmons et al., 2008) following
                                           modifications. HEK-293 cells resuspended Buffer (10mM Trisâ€“HCl pH 7.6, 1mM
                                           KAc, 1.5mM MgAc, 2mM DTT, 10Âµl/ml Protease Arrest inhibitors), lysed using Power
                                           Gen 500 homogenizer (Fisher Scientific, PA), followed centrifugation 12,000 Ã— g                                            10 min 4Â°C remove debris. Protein G Sepharose Fast Flow beads (Sigma-Aldrich,
                                           USA) incubated human TTP (kindly provided Dr. William Rigby, Dartmouth
                                           University) IgG antibody IP Buffer (10mM Tris-HCl pH 7.6, 1.5mM MgCl2,
                                           100mM NaCl, 0.5  Triton X-100, 10Âµl/ml Protease Arrest inhibitors) 4Â°C                                            continuous rotation 4 hours. Beads washed 6 times cold IP buffer                                            incubated HEK-293 lysate 4Â°C continuous rotation 2 hours. RNA                                            collected equal amounts amplified qRT-PCR. Expression gene                                            normalized 18S data expressed fold enrichment IgG control.
NIH-PA Author Manuscript




                              Luciferase Assay
                                           Luciferase assay TfR1-3â€™UTR-Luc various deletion constructs performed
                                           using Dual Glo Luciferase Assay (Promega) according manufacturerâ€™s
                                           protocol. 3â€™ UTR TfR1 cloned pMIR-report vector containing gene                                            firefly luciferase (Ambion) confirmed sequencing. luminescence quantified
                                           Berthold Technologies Luminometer (Germany) Dual-GloÂ® Stop & GloÂ®
                                           reagent added quench firefly luminescence provide substrate renilla
                                           luminescence used normalize transfection efficiency.

                              Cell death studies
                                           Cell death assessed labeling PI (Sigma-Aldrich, USA) Alexa FluorÂ®
                                           350-conjugated Annexin V (Molecular Probes, NY), analyzed flow cytometry                                            FacsCanto flow cytometer (BD Bioscience). cell-cycle studies, cells incubated
                                           rapamycin 6 hours incubated DFO rapamycin 10-hours prior                                            collection. Cells collected trypsinization, washed, fixed 70  ethanol                                            âˆ’20Â°C hours, followed incubation PI staining solution (50Âµg/mL PI,
                                           0.2mg/ml RNAse  0.1  Triton X-100 PBS) 37Â°C 20 minutes. Cell cycle NIH-PA Author Manuscript




                                           analyzed flow cytometry FlowJo 7.6 software.

                              Mouse studies
                                           Wild-type C57BL/6 females purchased Jackson labs treated 5 daily
                                           intraperitoneal injections rapamycin 10mg/kg DMSO. Mice anesthetized
                                           250mg/kg dose freshly-prepared Tribromoethanol (Avertin) harvested
                                           organs flash-frozen liquid nitrogen. animal studies conducted                                            accordance Northwestern University animal care guidelines.

                              Yeast studies
                                           Yeast cth1Î”cth2Î” cells transformed pRS416 vector expressing CTH2, TTP                                            TTP-C124R control CTH2 promoter region grown synthetic media
                                           containing 300ÂµM iron (+ Fe) 100ÂµM Fe2+-specific chelator bathophenanthroline
                                           disulfonic acid (âˆ’ Fe), RNA extracted analyzed RNA blotting previously

                                              Cell Metab. Author manuscript; available PMC 2013 November 07.
                            Bayeva et al.                                                                                                            Page 12


                                           described (Puig et al., 2005). Actin (ACT1) mRNA levels used loading control.
                                           Wild-type yeast cells exponential phase growth treated 1Âµg/mL                                            rapamycin 16 hours, following mRNA collected expression Cth1/2
NIH-PA Author Manuscript




                                           genes analyzed qRT-PCR.

                              Statistical analysis
                                           Data expressed mean Â± SEM. Statistical significance assessed unpaired
                                           Student t test; P value 0.05 considered statistically significant.

                              Supplementary Material
                                           Refer Web version PubMed Central supplementary material.


                              Acknowledgments
                                           thank Dr. Seth  Brooks help TTP RNA-CoIP experiments, Drs. Sarah Rice, Navdeep Chandel                                            Elizabeth Leibold critical review manuscript, Drs. William F.C. Rigby, M. Celeste Simon                                            Tracey  Rouault generous gifts human TTP antibody, ARNT KO MEFs, IRP1 2 KO
                                           MEFs respectively. work supported Northwestern University Flow Cytometry Facility                                            Cancer Center Support Grant (NCI CA060553). M.B. H  designed research. M.B., K. S.P.
                                           performed experiments data analysis. P.J.B S.P. provided tools reagents. M.B. wrote                                            manuscript, authors commented  H  supervised project. M.B. supported American
NIH-PA Author Manuscript




                                           Heart Association 10PRE4430021. H  supported NIH grants K02 HL107448 R01 HL087149.


                              REFERENCES
                                           Aisen P, Enns C, Wessling-Resnick M. Chemistry biology eukaryotic iron metabolism. Int J
                                             Biochem Cell Biol. 2001; 33:940â€“959. [PubMed: 11470229]
                                           Altamura S, Muckenthaler MU. Iron toxicity diseases aging: Alzheimer's disease, Parkinson's
                                             disease atherosclerosis. J Alzheimers Dis. 2009; 16:879â€“895. [PubMed: 19387120]
                                           Anderson GJ, Vulpe CD. Mammalian iron transport. Cell Mol Life Sci. 2009; 66:3241â€“3261.
                                             [PubMed: 19484405]
                                           Arredondo M, Nunez MT. Iron copper metabolism. Mol Aspects Med. 2005; 26:313â€“327.
                                             [PubMed: 16112186]
                                           Baou M, Jewell  Murphy JJ. TIS11 family proteins roles posttranscriptional gene
                                             regulation. J Biomed Biotechnol. 2009; 2009:634520. [PubMed: 19672455]
                                           Briata P, Ilengo C, Corte G, Moroni C, Rosenfeld MG, Chen CY, Gherzi R. Wnt/beta-catenin--
                                             >Pitx2 pathway controls turnover Pitx2 unstable mRNAs. Mol Cell. 2003;
                                             12:1201â€“1211. [PubMed: 14636578]
                                           Cao H, Tuttle JS, Blackshear PJ. Immunological characterization tristetraprolin low abundance,
NIH-PA Author Manuscript




                                             inducible, stable cytosolic protein. J Biol Chem. 2004; 279:21489â€“21499. [PubMed: 15010466]
                                           Carballo E, Blackshear PJ. Roles tumor necrosis factor-alpha receptor subtypes pathogenesis
                                             tristetraprolin-deficiency syndrome. Blood. 2001; 98:2389â€“2395. [PubMed: 11588035]
                                           Carrick DM, Lai WS, Blackshear PJ. tandem CCCH zinc finger protein tristetraprolin                                              relevance cytokine mRNA turnover arthritis. Arthritis Res Ther. 2004; 6:248â€“264. [PubMed:
                                             15535838]
                                           Dongiovanni P, Fracanzani AL, Fargion S, Valenti L. Iron fatty liver metabolic
                                               syndrome: promising therapeutic target. J Hepatol. 2011; 55:920â€“932. [PubMed: 21718726]
                                           Dongiovanni P, Valenti L, Ludovica Fracanzani  Gatti S, Cairo G, Fargion S. Iron depletion                                                deferoxamine regulates glucose uptake insulin signaling hepatoma cells rat liver.
                                               J Pathol. 2008; 172:738â€“747. [PubMed: 18245813]
                                           Dunlop EA, Tee AR. Mammalian target rapamycin complex 1: signalling inputs, substrates                                                feedback mechanisms. Cell Signal. 2009; 21:827â€“835. [PubMed: 19166929]




                                               Cell Metab. Author manuscript; available PMC 2013 November 07.
                            Bayeva et al.                                                                                                   Page 13


                                           Emmons J, Townley-Tilson WH, Deleault KM, Skinner SJ, Gross RH, Whitfield ML, Brooks SA.
                                               Identification TTP mRNA targets human dendritic cells reveals TTP critical regulator                                                dendritic cell maturation. RNA. 2008; 14:888â€“902. [PubMed: 18367721]
NIH-PA Author Manuscript




                                           Essafi-Benkhadir K, Onesto C, Stebe E, Moroni C, Pages G. Tristetraprolin inhibits Ras-dependent
                                               tumor vascularization inducing vascular endothelial growth factor mRNA degradation. Mol
                                               Biol Cell. 2007; 18:4648â€“4658. [PubMed: 17855506]
                                           Galvez T, Teruel MN, Heo WD, Jones JT, Kim ML, Liou J, Myers JW, Meyer T. siRNA screen                                                human signaling proteome identifies PtdIns(3,4,5)P3-mTOR signaling pathway primary
                                               regulator transferrin uptake. Genome Biol. 2007; 8:R142. [PubMed: 17640392]
                                           Hentze MW, Muckenthaler MU, Galy B, Camaschella C. tango: regulation Mammalian iron
                                               metabolism. Cell. 2010; 142:24â€“38. [PubMed: 20603012]
                                           Howell JJ, Manning BD. mTOR couples cellular nutrient sensing organismal metabolic
                                               homeostasis. Trends Endocrinol Metab. 2011; 22:94â€“102. [PubMed: 21269838]
                                           Kakuta K, Orino K, Yamamoto S, Watanabe K. High levels ferritin iron fetal bovine
                                               serum. Comp Biochem Physiol Physiol. 1997; 118:165â€“169. [PubMed: 9243818]
                                           Kim MJ, Mayr M, Pechula M, Steiger J, Dickenmann M. Marked erythrocyte microcytosis                                                primary immunosuppression sirolimus. Transpl Int. 2006; 19:12â€“18. [PubMed: 16359372]
                                           Lai WS, Carballo E, Strum JR, Kennington EA, Phillips RS, Blackshear PJ. Evidence                                                tristetraprolin binds AU-rich elements promotes deadenylation destabilization                                                tumor necrosis factor alpha mRNA. Mol Cell Biol. 1999; 19:4311â€“4323. [PubMed: 10330172]
                                           Liu Q, Sun L, Tan Y, Wang G, Lin X, Cai L. Role iron deficiency overload pathogenesis
NIH-PA Author Manuscript




                                               diabetes diabetic complications. Curr Med Chem. 2009; 16:113â€“129. [PubMed: 19149565]
                                           Maiorano  Stallone G, Schena  Infante B, Pontrelli P, Schena FP, Grandaliano G. Sirolimus
                                               interferes iron homeostasis renal transplant recipients. Transplantation. 2006; 82:908â€“912.
                                               [PubMed: 17038905]
                                           Maltepe E, Schmidt JV, Baunoch D, Bradfield CA, Simon MC. Abnormal angiogenesis responses
                                               glucose oxygen deprivation mice lacking protein ARNT. Nature. 1997; 386:403â€“407.
                                               [PubMed: 9121557]
                                           Ndong M, Kazami M, Suzuki T, Uehara M, Katsumata S, Inoue H, Kobayashi K, Tadokoro T, Suzuki
                                               K, Yamamoto Y. Iron deficiency regulates Akt/TSC1-TSC2/mammalian Target                                                Rapamycin signaling pathway rats COS-1 cells. Nutr Res. 2009; 29:640â€“647. [PubMed:
                                               19854379]
                                           Ohyashiki JH, Kobayashi C, Hamamura R, Okabe S, Tauchi T, Ohyashiki K. oral iron chelator
                                               deferasirox represses signaling mTOR myeloid leukemia cells enhancing
                                               expression REDD1. Cancer Sci. 2009; 100:970â€“977. [PubMed: 19298223]
                                           Patel SA, Simon MC. Biology hypoxia-inducible factor-2alpha development disease. Cell
                                               Death Differ. 2008; 15:628â€“634. [PubMed: 18259197]
                                           Pedro-Segura E, Vergara SV, Rodriguez-Navarro S, Parker R, Thiele DJ, Puig S. Cth2 
                                               binding protein recruits Dhh1 helicase promote decay succinate dehydrogenase SDH4
                                               mRNA response iron deficiency. J Biol Chem. 2008; 283:28527â€“28535. [PubMed:
NIH-PA Author Manuscript




                                               18715869]
                                           Puig S, Askeland E, Thiele DJ. Coordinated remodeling cellular metabolism iron deficiency
                                               targeted mRNA degradation. Cell. 2005; 120:99â€“110. [PubMed: 15652485]
                                           Puig S, Vergara SV, Thiele DJ. Cooperation mRNA-binding proteins drives metabolic
                                               adaptation iron deficiency. Cell Metab. 2008; 7:555â€“564. [PubMed: 18522836]
                                           Rebouche CJ, Wilcox CL, Widness JA. Microanalysis non-heme iron animal tissues. J Biochem
                                               Biophys Methods. 2004; 58:239â€“251. [PubMed: 15026210]
                                           Rouault TA. role iron regulatory proteins mammalian iron homeostasis disease. Nat
                                               Chem Biol. 2006; 2:406â€“414. [PubMed: 16850017]
                                           Sengupta S, Peterson TR, Sabatini DM. Regulation mTOR complex 1 pathway nutrients,
                                               growth factors, stress. Mol Cell. 2010; 40:310â€“322. [PubMed: 20965424]
                                           Sofroniadou S, Kassimatis T, Goldsmith D. Anaemia, microcytosis sirolimus- iron missing
                                               link? Nephrol Dial Transplant. 2010; 25:1667â€“1675. [PubMed: 20054028]



                                               Cell Metab. Author manuscript; available PMC 2013 November 07.
                            Bayeva et al.                                                                                                Page 14


                                           Soliman GA. mammalian target rapamycin signaling network gene regulation. Curr Opin
                                               Lipidol. 2005; 16:317â€“323. [PubMed: 15891393]
                                           Taylor GA, Carballo E, Lee DM, Lai WS, Thompson MJ, Patel DD, Schenkman DI, Gilkeson GS,
NIH-PA Author Manuscript




                                               Broxmeyer  Haynes BF, et al. pathogenetic role TNF alpha syndrome cachexia,
                                               arthritis, autoimmunity resulting tristetraprolin (TTP) deficiency. Immunity. 1996;
                                               4:445â€“454. [PubMed: 8630730]
                                           Torti SV, Torti FM. Ironing cancer. Cancer Res. 2011; 71:1511â€“1514. [PubMed: 21363917]
                                           Wang J, Pantopoulos K. Regulation cellular iron metabolism. Biochem J. 2011; 434:365â€“381.
                                               [PubMed: 21348856]
                                           Ward JH, Jordan  Kushner JP, Kaplan J. Heme regulation HeLa cell transferrin receptor number. J
                                               Biol Chem. 1984; 259:13235â€“13240. [PubMed: 6092369]
                                           Weinberg ED. hazards iron loading. Metallomics. 2010; 2:732â€“740. [PubMed: 21072364]
                                            Worldwide prevalence anaemia 1993â€“2005. Geneva, Switzerland: Press; 2008.
                                           Zhang H, Cicchetti G, Onda H, Koon HB, Asrican K, Bajraszewski N, Vazquez F, Carpenter CL,
                                               Kwiatkowski DJ. Loss Tsc1/Tsc2 activates mTOR disrupts PI3K-Akt signaling                                                downregulation PDGFR. J Clin Invest. 2003; 112:1223â€“1233. [PubMed: 14561707]
NIH-PA Author Manuscript
NIH-PA Author Manuscript




                                               Cell Metab. Author manuscript; available PMC 2013 November 07.
                            Bayeva et al.                                                                                      Page 15


                                                                                 HIGHLIGHTS
                                           â€¢    mTOR regulates iron homeostasis altering expression iron transporters
NIH-PA Author Manuscript




                                           â€¢    TTP regulates iron homeostasis, similar yeast Cth1p/2p
                                           â€¢    mTOR regulates TfR1 iron homeostasis TTP
                                           â€¢    TfR1 mRNA target TTP
NIH-PA Author Manuscript
NIH-PA Author Manuscript




                                           Cell Metab. Author manuscript; available PMC 2013 November 07.
                            Bayeva et al.                                                                                        Page 16
NIH-PA Author Manuscript
NIH-PA Author Manuscript
NIH-PA Author Manuscript




                                           Figure 1. mTOR regulates cellular iron content uptake
                                             mTOR modulation MEFs (left) H9c2 (right) cells assessed Western blot                                            phosphorylated S6 protein. Densitometry analysis shown Western blot (n=3).
                                           TSC2 protein levels (right) TSC2 KO-V TSC2 KO-TSC2 MEFs. (B) Non-heme iron
                                           content WT MEFs treated 20nM rapamycin 48 hrs normalized protein
                                           concentration (n=12). subsequent experiments carried 20nM rapamycin
                                           treatment 48 hrs mammalian cell lines, unless noted  (C) Non-heme iron
                                           content TSC2 KO-V TSC2 KO-TSC2 MEFs rapamycin treatment
                                           (n=6â€“12). (D) Radioactive iron uptake 1 hour WT MEFs rapamycin vehicle


                                               Cell Metab. Author manuscript; available PMC 2013 November 07.
                            Bayeva et al.                                                                                    Page 17


                                           control treatment (n=12). (E) Radioactive iron uptake 1 hour TSC2 KO-V TSC2
                                           KO-TSC2 MEFs rapamycin (n=6â€“12). (F) Cellular content 55Fe WT
                                           MEFs treated rapamycin vehicle control following 24-hour incubation NIH-PA Author Manuscript




                                           radioactive iron (n=12). (G) Cellular content 55Fe TSC2 KO-V TSC2 KO-TSC2
                                           MEFs rapamycin following 24-hour incubation radioactive iron
                                           (n=6). Data presented mean Â± SEM. * p<0.05 vs. control, # p<0.05 vs. TSC2 KO-V
                                           MEFs. Figure S1.
NIH-PA Author Manuscript
NIH-PA Author Manuscript




                                              Cell Metab. Author manuscript; available PMC 2013 November 07.
                            Bayeva et al.                                                                                      Page 18
NIH-PA Author Manuscript
NIH-PA Author Manuscript
NIH-PA Author Manuscript




                                           Figure 2. mTOR regulates expression iron transporters
                                           Protein levels TfR1 WT MEFs   Fpn1 mouse hearts (B) following rapamycin
                                           treatment. Densitometry analyses presented Western blots. (C) mRNA levels
                                           iron transporters, TfR1 Fpn1, determined qRT-PCR, WT MEFs                                            rapamycin treatment (n=6â€“12). (D) mRNA levels iron transporters TSC2 KO-
                                           V TSC2 KO-TSC2 MEFs rapamycin treatment (n=6â€“12). (E) mRNA
                                           levels genes unrelated iron homeostasis WT MEFs treated rapamycin vehicle
                                           control (n=6). Data presented mean Â± SEM. * p<0.05 vs. control, # p<0.05 vs. TSC2
                                           KO-V MEFs. Figure S2.


                                               Cell Metab. Author manuscript; available PMC 2013 November 07.
                            Bayeva et al.                                                                                       Page 19
NIH-PA Author Manuscript
NIH-PA Author Manuscript
NIH-PA Author Manuscript




                                           Figure 3. TTP functionally similar yeast Cth1p/2p
                                             Time-course TfR1 Fpn1 mRNA regulation rapamycin WT MEFs 24
                                           hrs (n=12â€“18). (B) TfR1 mRNA stability WT MEFs rapamycin pre-
                                           treatment assessed qRT-PCR incubation transcriptional inhibitor
                                           actinomycin D (act D), normalized TfR1 mRNA levels time point zero respective
                                           group (n=3). (C) IRP1 mRNA levels IRP2 KO MEFs following treatment IRP1
                                           siRNA (n=6). (D) TfR1 mRNA levels IRP1/2 KD/KO MEFs following rapamycin
                                           treatment (n=6). TTP mRNA (E) TTP protein (F) levels WT MEFs DFO
                                           treatment 16 hours (n=3â€“6). Densitometry analysis presented Western blot.


                                               Cell Metab. Author manuscript; available PMC 2013 November 07.
                            Bayeva et al.                                                                                       Page 20


                                           (G) TTP mRNA levels H9c2 cells 16-hour incubation 2,2-BPD FAC iron
                                           chelation overload, respectively (n=6). (H) mRNA levels iron-containing proteins                                            WT MEFs treated 150ÂµM DFO 16 hours (n=6). Unless noted  NIH-PA Author Manuscript




                                           subsequent studies performed using protocol iron chelation DFO.  
                                           mRNA levels iron-containing proteins TTP WT KO MEFs (n=12â€“18). (J) mRNA
                                           levels iron-containing proteins TTP KO WT MEFs presence absence                                            DFO (n=6â€“12). (K) mRNA levels iron-containing Cth2p targets cth1Î”cth2Î” yeast
                                           ectopic expression human wild-type TZF mutant TTP. Data presented                                            mean Â± SEM. * p<0.05 vs. control, # p<0.05 vs. control 180 minutes. Figure S3.
NIH-PA Author Manuscript
NIH-PA Author Manuscript




                                              Cell Metab. Author manuscript; available PMC 2013 November 07.
                            Bayeva et al.                                                                                  Page 21
NIH-PA Author Manuscript
NIH-PA Author Manuscript
NIH-PA Author Manuscript




                                           Figure 4. mTOR regulates TTP expression
                                           TTP mRNA   TTP protein (B) levels WT MEFs treated rapamycin (n=6â€“8).
                                           (C) TTP mRNA levels TSC2 KO-V TSC2 KO-TSC2 MEFs                                            rapamycin treatment (n=6â€“12). (D) Cth1 Cth2 mRNA levels WT yeast cells treated
                                           1Âµg/mL rapamycin 24 hours (n=6). mRNA levels TTP ARNT KO MEFs
                                           treated rapamycin (E) DFO (F) (n=15). TTP mRNA levels IRP1/2 KD/KO MEFs
                                           treated rapamycin (G) DFO (H) (n=6).   TfR1 mRNA levels TTP KO                                            control MEFs (n=15). (J) TfR1 mRNA levels WT MEFs transfected TTP- GFP-
                                           containing (control) vectors (n=6). (K) TfR1 mRNA stability TTP WT KO MEFs


                                              Cell Metab. Author manuscript; available PMC 2013 November 07.
                            Bayeva et al.                                                                                         Page 22


                                           treated transcriptional inhibitor act D (n=6). Data presented mean Â± SEM. *
                                           p<0.05 vs. control. Figure S4.
NIH-PA Author Manuscript
NIH-PA Author Manuscript
NIH-PA Author Manuscript




                                               Cell Metab. Author manuscript; available PMC 2013 November 07.
                            Bayeva et al.                                                                                       Page 23
NIH-PA Author Manuscript
NIH-PA Author Manuscript
NIH-PA Author Manuscript




                                           Figure 5. mTOR regulates TfR1 TTP
                                             Schematic representation TfR1-3â€™UTR-Luc construct IREs indicated white
                                           putative AREs grey. Luciferase assay TfR1-3â€™UTR activity WT MEFs
                                           overexpressing TTP (B) TTP KO WT MEFs (C), normalized renilla luciferase
                                           (n=6). (D) mRNA levels TfR1 total RNA precipitated TTP IgG (control)
                                           antibodies HEK293 cells. primer sets targeting different regions near 3â€™UTR                                            TfR1 gene used RNA IP assay normalized 18S internal control.
                                           Data presented fold enrichment IgG control (n=3). (E) mRNA levels TfR1
                                           TTP WT KO MEFs treated rapamycin vehicle control (n=12). (F) mRNA


                                              Cell Metab. Author manuscript; available PMC 2013 November 07.
                            Bayeva et al.                                                                                      Page 24


                                           levels ABCE1 Lias TTP WT KO MEFs rapamycin treatment
                                           (n=12). (G) TfR1 mRNA stability 3-hour incubation act D WT TTP KO
                                           MEFs presence absence rapamycin. Data presented fold change TfR1
NIH-PA Author Manuscript




                                           mRNA levels time point zero respective group (n=3â€“6). (H) TfR1 mRNA levels
                                           TTP WT KO MEFs DFO treatment (n=6).   Cell death assessed
                                           propidium iodine (PI) Annexin V labeling flow cytometry TTP WT KO
                                           MEFs treated 250ÂµM DFO 250ÂµM 2,2-BPD 40 hours normalized                                            vehicle-treated control (n=4). (J) Cell death TTP KO MEFs 16-hour pre-
                                           treatment rapamycin incubated 250ÂµM DFO 250ÂµM 2,2-BPD 40 hours                                            rapamycin (n=4). Data presented mean Â± SEM. * p<0.05 vs. control, #
                                           p<0.05 vs. rapamycin pre-treated control group. Rapa, rapamycin. Figure S5.
NIH-PA Author Manuscript
NIH-PA Author Manuscript




                                              Cell Metab. Author manuscript; available PMC 2013 November 07.
                            Bayeva et al.                                                                                       Page 25
NIH-PA Author Manuscript
NIH-PA Author Manuscript
NIH-PA Author Manuscript




                                           Figure 6. vivo regulation iron homeostasis mTOR TTP
                                           Non-heme   heme (B) iron levels hearts c57 black WT mice treated 5
                                           daily IP injections rapamycin, 10mg/kg (n=6), equal volume DMSO vehicle. (C)
                                           TfR1 Fpn1 mRNA levels hearts rapamycin-treated mice (n=6). (D) Western
                                           blot analysis rapamycin-treated mouse hearts. Densitometry analysis presented                                            Western blots (n=3). (E). Western blot analysis TfR1 protein hearts TTP/
                                           TNFR1/2 KO (designated TTP KO) matched littermate WT control mice (designated
                                           TTP WT). Densitometry analysis presented right Western blot (n=3). (F)
                                           Non-heme iron levels hearts TTP KO WT mice (n=4). (G) Western blot


                                              Cell Metab. Author manuscript; available PMC 2013 November 07.
                            Bayeva et al.                                                                                         Page 26


                                           analysis ferritin light heavy chains (FtL + FtH) Fpn1 proteins hearts                                            TTP KO WT mice. Densitometry analysis presented Western blots (n=4).
                                           (H) Model cellular iron regulation mTOR TTP. Data presented mean Â±
NIH-PA Author Manuscript




                                           SEM. * p<0.05. Figure S6.
NIH-PA Author Manuscript
NIH-PA Author Manuscript




                                              Cell Metab. Author manuscript; available PMC 2013 November 07.
                            Bayeva et al.                                                                                      Page 27




                                                                                        Table 1
                                                Interaction TTP TfR1 mRNA
NIH-PA Author Manuscript




                           RNA-CoIP experiment using specific TTP antibody control IgG antibody bait establishes physical
                           interaction TTP TfR1 mRNA. distinct sets primers designed target regions                            TfR1 mRNA adjacent 3â€™UTR. Relative mRNA levels assessed qRT-PCR displayed                            fold enrichment IgG control. VEGF1 Pitx-2 used positive controls, Î²2-microglobulin,
                           Fpn1, HPRT 18S rRNA used negative controls. Figure S6

                            Gene                    Relative Expression   Relative Expression   Fold Enrichment
                                                    IgG                   TTP                   IgG Control

                            Transferrin Receptor

                              TfR1-1                281.81                426.31                1.51

                              TfR1-2                528.61                672.54                1.27

                              TfR1-3                268.16                381.56                1.42

                              TfR1-4                266.13                369.66                1.45

                            Positive Controls

                              VEGF-1                1931.18               3678.42               1.90

                              VEGF-2                2048.95               3982.25               1.94
NIH-PA Author Manuscript




                              Pitx2-1               2082.60               1960.18               0.94

                              Pitx2-2               690.53                984.72                1.43

                            Negative Controls

                              Î²2MG                  22080.25              19099.78              0.87

                   